ArriVent BioPharma (AVBP) Institutional Ownership
13F filers reported holding 100.1% of ArriVent BioPharma (AVBP) shares as of Sep 30, 2026, across 154 filers.
- Held by 13F filers
- 100.1%
- Sep 30, 2026
- 13F filers
- 154
- quarter ended Sep 30, 2026
- 13F value
- $1.6B
- 51.8M shares
- Quarter's fund flow
- Mild accumulation
- 17 new · 18 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Acquired · Option exercise | 16,265 | $3.65 | ↗ |
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Acquired · Option exercise | 410 | $2.28 | ↗ |
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Acquired · Option exercise | 4,550 | $2.28 | ↗ |
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Acquired · Option exercise | 1,820 | $2.28 | ↗ |
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Acquired · Option exercise | 17,648 | $6.24 | ↗ |
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Disposed · Option exercise | 410Stock Option (right to buy) | — | ↗ |
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Disposed · Option exercise | 4,550Stock Option (right to buy) | — | ↗ |
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Disposed · Option exercise | 1,820Stock Option (right to buy) | — | ↗ |
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Disposed · Option exercise | 16,265Stock Option (right to buy) | — | ↗ |
| Oct 30, 2026 | LaChapelle Robin | Chief Operating Officer | Disposed · Option exercise | 17,648Stock Option (right to buy) | — | ↗ |
| Jun 18, 2026 | Parsey Merdad | director | Acquired · Grant / award | 13,562Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 18, 2026 | Peterson Kristine | director | Acquired · Grant / award | 13,562Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 18, 2026 | Hohneker John | director | Acquired · Grant / award | 13,562Non-Qualified Stock Option (right to buy) | — | ↗ |
| Jun 18, 2026 | Nolet Chris | director | Acquired · Grant / award | 13,562Non-Qualified Stock Option (right to buy) | — | ↗ |
| Feb 2, 2026 | LaChapelle Robin | Chief Operating Officer | Acquired · Grant / award | 130,000Stock Option (right to buy) | — | ↗ |
| Feb 2, 2026 | Lutzker Stuart | President of R&D | Acquired · Grant / award | 150,000Stock Option (right to buy) | — | ↗ |
| Feb 2, 2026 | Kung Winston | Chief Financial Officer | Acquired · Grant / award | 140,000Stock Option (right to buy) | — | ↗ |
| Feb 2, 2026 | Yao Zhengbin | President and CEO | Acquired · Grant / award | 550,000Stock Option (right to buy) | — | ↗ |
| Feb 2, 2026 | Kastenmayer James Paul | General Counsel | Acquired · Grant / award | 130,000Stock Option (right to buy) | — | ↗ |
| Dec 10, 2025 | Hillhouse Capital Management, Ltd. | 10% owner | Disposed · Open-market sale | 555,555 | $23.37 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of ArriVent BioPharma do institutions hold?
13F filers reported holding 100.1% of ArriVent BioPharma's shares as of Sep 30, 2026, across 154 filers.
How many 13F filers hold ArriVent BioPharma?
ArriVent BioPharma was held by 154 13F filers as of Sep 30, 2026.
Not investment advice.

